Cardiac Computed Tomography Based 3-D Printing for Optimized Coronary Artery Bypass Graft Surgery
Launched by JESPER JAMES LINDE · Jun 18, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help improve heart bypass surgery, which is a common treatment for people with serious blockages in their heart arteries. Sometimes, the new blood vessels used in the surgery can close up within a year, which can cause problems later on. This study is testing whether using a 3-D printed model of a patient’s heart arteries—made from special heart scans before surgery—can help surgeons place the new vessels more accurately and reduce the chance of these vessels closing.
People who might be eligible for this study are adults aged 65 to 74 who need heart bypass surgery, as decided by their medical team. They should be planned for a specific type of bypass involving certain heart arteries. Patients with certain conditions, like severe kidney problems, irregular heart rhythms, or those who are pregnant, would not be eligible. If you join the study, you will have extra heart scans before surgery to create a 3-D model of your heart arteries. The surgeons will then use this model during your operation to guide them. After one year, you will have another scan to see how well the bypass vessels are working. This study aims to find out if this new approach can help make heart bypass surgery safer and more effective.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Indication for CABG (with or without valve-surgery), determined by heart team conference. The revascularization plan must include further grafting in addition LIMA to LAD.
- Exclusion Criteria:
- • Age \<18 years
- • Permanent atrial fibrillation
- • Renal failure (eGRF \< 30)
- • Known allergy to contrast material
- • Pregnant and/or breastfeeding
- • Indication for acute CABG
- • Patients who cannot tolerate premedication with nitroglycerin and beta blocker (including LVEF\<40%). This applies only to the pre-operative CT scan.
About Jesper James Linde
Jesper James Linde is a clinical trial sponsor dedicated to advancing medical research through the design and support of innovative clinical studies. Committed to scientific rigor and patient safety, Jesper James Linde focuses on fostering developments that contribute to improved healthcare outcomes and evidence-based treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported